William G. Gerber

William G. Gerber

"Dr. Gerber is a Partner at Bay City Capital and joined the company in September 1999. He was most recently Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen, Inc. in December 2004. Prior to joining Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, President of Chiron Diagnostics, and Senior Vice President and General Manager of the PCR Division with Cetus Corporation. He is Chairman of the Board of Directors of Pathway Diagnostics and a member of the Board of Directors of Galileo Pharmaceuticals, Nanogen, Inc., Radiant Medical, Inc. and Sangamo Biosciences. He also served on and was President of the Board of Medical Quality Assurance, State of California. Dr. Gerber received his M.D. and B.S. from University of California, San Francisco Medical Center after attending Dartmouth College."